{"id":"NCT02715258","sponsor":"Theracos","briefTitle":"Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes","officialTitle":"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Compare the Efficacy and Safety of Bexagliflozin to Placebo in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03","primaryCompletion":"2017-04","completion":"2017-04","firstPosted":"2016-03-22","resultsPosted":"2021-04-28","lastUpdate":"2021-06-28"},"enrollment":210,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Bexagliflozin","otherNames":["EGT0001442"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Bexagliflozin tablets, 20 mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo tablets","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).","primaryOutcome":{"measure":"Change in HbA1c From Baseline at Week 24","timeFrame":"24 weeks","effectByArm":[{"arm":"Bexagliflozin Tablets, 20 mg","deltaMin":-0.51,"sd":0.082},{"arm":"Placebo Tablets","deltaMin":-0.1,"sd":0.108}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0012"},{"comp":"OG000 vs OG001","p":"0.0021"},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"0.0009"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":23,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":138},"commonTop":["Polyuria","Abdominal pain","Diarrhea","Urinary tract infection","Headache"]}}